Mifamurtide sodium hydrate | CAS#838853-48-8 | a macrophage activator

MedKoo Cat#: 596747 | Name: Mifamurtide sodium hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mifamurtide protects mice against herpes simplex virus type 2; a macrophage activator; called muramyl tripeptide but that term is ambiguous, confused with other tripeptides of muramic acid.

Chemical Structure

Mifamurtide sodium hydrate

CAS#838853-48-8 (sodium hydrate)

Theoretical Analysis

MedKoo Cat#: 596747

Name: Mifamurtide sodium hydrate

CAS#: 838853-48-8 (sodium hydrate)

Chemical Formula: C59H110N6NaO20P

Exact Mass:

Molecular Weight: 1277.51

Elemental Analysis: C, 55.47; H, 8.68; N, 6.58; Na, 1.80; O, 25.05; P, 2.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

83461-56-7 (free acid) 90825-43-7 (sodium) 838853-48-8 (sodium hydrate)

Synonym

Mifamurtide; Muramyl tripeptide; L-MTP-PE;

IUPAC/Chemical Name

sodium 2-(2-(((2S,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)oxy)-N-((S)-1-((R)-5-amino-2-((S)-2-aminopropanamido)-5-oxopentanamido)-1-oxopropan-2-yl)propanamido)ethyl ((R)-2,3-bis(palmitoyloxy)propyl) phosphate hydrate

InChi Key

UGLNJSJKBHIHCX-BWJKLZNOSA-M

InChi Code

InChI=1S/C59H109N6O19P.Na.H2O/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-50(69)79-40-46(83-51(70)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)41-81-85(77,78)80-38-37-65(43(4)56(73)64-57(74)47(35-36-49(61)68)63-55(72)42(3)60)58(75)44(5)82-54-52(62-45(6)67)59(76)84-48(39-66)53(54)71;;/h42-44,46-48,52-54,59,66,71,76H,7-41,60H2,1-6H3,(H2,61,68)(H,62,67)(H,63,72)(H,77,78)(H,64,73,74);;1H2/q;+1;/p-1/t42-,43-,44?,46+,47+,48+,52+,53+,54+,59-;;/m0../s1

SMILES Code

C[C@@H](C(NC([C@H](NC([C@H](C)N)=O)CCC(N)=O)=O)=O)N(C(C(O[C@H]1[C@@H]([C@H](O[C@@H]([C@@H]1NC(C)=O)O)CO)O)C)=O)CCOP(OC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)([O-])=O.[H]O[H].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,277.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Signorell RD, Luciani P, Brambilla D, Leroux JC. Pharmacokinetics of lipid-drug conjugates loaded into liposomes. Eur J Pharm Biopharm. 2018 Jul;128:188-199. doi: 10.1016/j.ejpb.2018.04.003. Epub 2018 Apr 18. Review. PubMed PMID: 29678733. 2: Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 Dec 19;5(1):100. doi: 10.1186/s40425-017-0301-y. PubMed PMID: 29254498; PubMed Central PMCID: PMC5735899. 3: Jimmy R, Stern C, Lisy K, White S. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review. JBI Database System Rev Implement Rep. 2017 Aug;15(8):2113-2152. doi: 10.11124/JBISRIR-2016-003105. Review. PubMed PMID: 28800058. 4: Cavallari JF, Fullerton MD, Duggan BM, Foley KP, Denou E, Smith BK, Desjardins EM, Henriksbo BD, Kim KJ, Tuinema BR, Stearns JC, Prescott D, Rosenstiel P, Coombes BK, Steinberg GR, Schertzer JD. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3. doi: 10.1016/j.cmet.2017.03.021. Epub 2017 Apr 20. PubMed PMID: 28434881. 5: Harrison DJ, Schwartz CL. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease. Curr Treat Options Oncol. 2017 Apr;18(4):24. doi: 10.1007/s11864-017-0464-2. Review. PubMed PMID: 28391422. 6: Anderson PM. Immune Therapy for Sarcomas. Adv Exp Med Biol. 2017;995:127-140. doi: 10.1007/978-3-319-53156-4_6. Review. PubMed PMID: 28321815. 7: Bellini G, Di Pinto D, Tortora C, Manzo I, Punzo F, Casale F, Rossi F. The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma. Curr Cancer Drug Targets. 2017;17(7):650-656. doi: 10.2174/1568009616666161215163426. PubMed PMID: 27993113. 8: Kebudi R, Ozger H, Kızılocak H, Bay SB, Bilgiç B. Osteosarcoma After Hematopoietic Stem Cell Transplantation in Children and Adolescents: Case Report and Review of the Literature. Pediatr Blood Cancer. 2016 Sep;63(9):1664-6. doi: 10.1002/pbc.26067. Epub 2016 May 17. Review. PubMed PMID: 27187839. 9: Biteau K, Guiho R, Chatelais M, Taurelle J, Chesneau J, Corradini N, Heymann D, Redini F. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89. eCollection 2016. PubMed PMID: 27152244; PubMed Central PMCID: PMC4851846. 10: Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015;16(18):2727-36. doi: 10.1517/14656566.2015.1102226. Epub 2015 Oct 29. Review. PubMed PMID: 26512909. 11: Winstone J, Chadda S, Ralston S, Sajosi P. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments. Orphanet J Rare Dis. 2015 Oct 28;10:139. doi: 10.1186/s13023-015-0349-z. Review. PubMed PMID: 26511061; PubMed Central PMCID: PMC4625856. 12: Song HJ, Lee JA, Han E, Lee EK. Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis. Tumour Biol. 2015 Sep;36(9):6773-9. doi: 10.1007/s13277-015-3405-3. Epub 2015 Apr 3. PubMed PMID: 25835978. 13: Brosa M, García del MX, Mora J, Villacampa A, Pozo T, Adán C, Grande M, García E, Cubells L. Economic Considerations On the Use of Mifamurtide In the Treatment of Osteosarcoma In Spain. Value Health. 2014 Nov;17(7):A526-7. doi: 10.1016/j.jval.2014.08.1662. Epub 2014 Oct 26. PubMed PMID: 27201662. 14: Brosa M, García del Muro X, Mora J, Villacampa A, Pozo-Rubio T, Cubells L, Montoto C. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):331-40. doi: 10.1586/14737167.2015.972378. Epub 2014 Oct 29. PubMed PMID: 25354299. 15: Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014 Nov;14(11):722-35. doi: 10.1038/nrc3838. Epub 2014 Oct 16. Review. PubMed PMID: 25319867. 16: O'Mahony JF, Paulden M. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. Value Health. 2014 Jul;17(5):493-6. doi: 10.1016/j.jval.2013.02.014. Epub 2013 May 15. PubMed PMID: 25128041. 17: Meyers PA, Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Review. PubMed PMID: 24924182. 18: Rodriguez CO Jr. Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks? Adv Exp Med Biol. 2014;804:237-56. doi: 10.1007/978-3-319-04843-7_13. Review. PubMed PMID: 24924178. 19: Song HJ, Lee EK, Lee JA, Kim HL, Jang KW. The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis. Tumour Biol. 2014 Sep;35(9):8771-9. doi: 10.1007/s13277-014-2139-y. Epub 2014 May 30. PubMed PMID: 24874050. 20: Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, Jiskoot W, Lankester AC, Schilham MW. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. J Exp Clin Cancer Res. 2014 Mar 10;33:27. doi: 10.1186/1756-9966-33-27. PubMed PMID: 24612598; PubMed Central PMCID: PMC4007518.